{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PH1&page=2", "query": { "condition": "PH1", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PH1&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-03T21:48:33.946Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02102022", "title": "Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Gastrointestinal (GI) Malignancies", "Hepatocellular Carcinoma", "Gastric Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "ADI-PEG 20 plus modified FOLFOX6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Polaris Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2014-11", "completion_date": "2020-02", "has_results": false, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-09-03T21:48:33.946Z", "location_count": 10, "location_summary": "San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02102022" }, { "nct_id": "NCT06839235", "title": "Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Primary Hyperoxaluria Type 1 (PH1)" ], "interventions": [ { "name": "ABO-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arbor Biotechnologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "6 Years to 64 Years" }, "enrollment_count": 23, "start_date": "2025-06-16", "completion_date": "2043-02", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-09-03T21:48:33.946Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Saint Paul, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06839235" }, { "nct_id": "NCT02923466", "title": "Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Solid Tumour" ], "interventions": [ { "name": "VSV-IFNβ-NIS", "type": "BIOLOGICAL" }, { "name": "VSV-IFNβ-NIS and avelumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vyriad, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2017-04-17", "completion_date": "2022-04-22", "has_results": false, "last_update_posted_date": "2022-04-27", "last_synced_at": "2026-09-03T21:48:33.946Z", "location_count": 6, "location_summary": "Miami, Florida • Minneapolis, Minnesota • Columbus, Ohio + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Sioux Falls", "state": "South Dakota" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02923466" }, { "nct_id": "NCT06943378", "title": "Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults" ], "interventions": [ { "name": "Monoclonal antibody JST-010", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Just-Evotec Biologics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 104, "start_date": "2025-05-16", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-09-03T21:48:33.946Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT06943378" }, { "nct_id": "NCT03504488", "title": "CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Triple Negative Breast Cancer", "Melanoma", "Head and Neck Cancer" ], "interventions": [ { "name": "CAB-ROR2-ADC", "type": "BIOLOGICAL" }, { "name": "PD-1 inhibitor", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioAtla, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2018-06-27", "completion_date": "2024-12-30", "has_results": false, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-09-03T21:48:33.946Z", "location_count": 38, "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03504488" }, { "nct_id": "NCT04510649", "title": "Surufatinib DDI With a PPI and a CYP3A Inducer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Part A", "type": "DRUG" }, { "name": "Part B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchison Medipharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 28, "start_date": "2020-07-09", "completion_date": "2021-03-02", "has_results": false, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-09-03T21:48:33.946Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04510649" }, { "nct_id": "NCT02029690", "title": "Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pleural Mesothelioma Malignant Advanced", "Peritoneal Mesothelioma Malignant Advanced", "Non-squamous Non-small Cell Lung Carcinoma", "Uveal Melanoma", "Hepatocellular Carcinoma", "Glioma", "Sarcomatoid Carcinoma" ], "interventions": [ { "name": "ADI-PEG 20", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Polaris Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2014-04-23", "completion_date": "2020-06", "has_results": false, "last_update_posted_date": "2020-09-25", "last_synced_at": "2026-09-03T21:48:33.946Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02029690" }, { "nct_id": "NCT04502888", "title": "Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Squamous Cell Carcinoma", "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "Drug: SL-172154", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shattuck Labs, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2020-09-17", "completion_date": "2022-04-08", "has_results": true, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-09-03T21:48:33.946Z", "location_count": 6, "location_summary": "Los Angeles, California • Boston, Massachusetts • Chapel Hill, North Carolina + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04502888" }, { "nct_id": "NCT02923986", "title": "Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myelogenous Leukemia, Ph1-Positive", "Acute Myeloid Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "BP1001 (varying dose)", "type": "DRUG" }, { "name": "BP1001 (fixed dose)", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bio-Path Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-09-01", "completion_date": "2020-05-27", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-09-03T21:48:33.946Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02923986" }, { "nct_id": "NCT00412412", "title": "CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "CNF2024", "type": "DRUG" }, { "name": "CNF2024 + trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2007-12", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2012-06-08", "last_synced_at": "2026-09-03T21:48:33.946Z", "location_count": 3, "location_summary": "Tampa, Florida • New York, New York • Houston, Texas", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00412412" } ] }